Cambridge, UK, May 5, 2026: Cellular Origins, enabling the manufacturing of cell therapies at scale, today announced a collaboration with Immatics (NASDAQ: IMTX), a late-stage clinical biopharmaceutical company and the global leader in precision targeting of PRAME for the production of Immatics’ immuno-oncology cell therapies.

Under the agreement, the Parties are working to utilise Cellular Origin’s automated mobile robotic platform, Constellation®, within certain parts of the company’s manufacturing processes. The collaboration will explore how automation technologies can further contribute to more efficient and scalable manufacturing processes for next-generation cell therapies.

Automation is increasingly recognised as an important enhancer for the broader adoption of cell therapies by helping optimise manufacturing consistency, scalability, and operational efficiency. Under the collaboration, Immatics is working with Cellular Origins on the Constellation platform for the automation of selected manufacturing operations. Cellular Origins’ experience and progress in integrating technologies from leading CGT equipment suppliers was an important factor in the decision. The programme is planned to be delivered in a series of defined phases and milestones, with the initial phase expected for completion in 2026.

“Following the first cell therapy approvals in 2017, there has been widespread success in treating blood cancers, while progress in solid tumours has been more limited. Immatics is now working to advance clinically validated approaches that could expand treatment options for these,” said Edwin Stone, CEO, Cellular Origins. “Current manual manufacturing methods can limit the number of patients who are able to access approved therapies. Effective cell therapies for solid-tumour patients is one of the most exciting developments in our field but will need the manufacturing challenges to be addressed to deliver on its potential. Our partnership with Immatics aims to support the scalable and cost-effective manufacturing of their therapies so that more patients could potentially benefit.”

“Immatics has generated extensive data demonstrating the potential of precision targeting PRAME, a target expressed in more than 50 cancers,” said Ali Mohamed, SVP, of CMC, Immatics. “As we continue to advance our programs, it is important that we also develop manufacturing capabilities that can support future scale. We are pleased to collaborate with Cellular Origins to explore how the Constellation platform and our integrated manufacturing processes could support the scalable production of our therapies as we move toward potential approvals.”

About Cellular Origins www.cellularorigins.com 

Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem unites mobile robotics, and automated sterile welding with proven bioprocess instruments, eliminating the need for therapy redevelopment and providing a dependable route from clinical to commercial manufacture. Designed to flex around any facility and to evolve with advancing therapies, the Constellation platform provides a flexible, future-proof foundation for large scale production and wider ATMP growth. Trusted by market leaders including Cytiva, Fresenius Kabi, Thermo Fisher Scientific and Wilson Wolf, Cellular Origins is building the automation infrastructure required to scale manufacture of 100,000s of doses of transformative therapies reliably and efficiently.

Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.